메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Public Interest Registry Unveils Winners of 7th Annual .ORG Impact Awards at DC Ceremony Hosted by Grammy-Award Winning Artist Common

The Fund for Congolese Women named 2025 .ORG of the Year, selected from nearly 3,000 applicants from more than 120 countries WASHINGTON, Oct. 8, 2025 -- Public Interest Registry (PIR), the people behind the .ORG domain, announced the winners of the 2025 ORG Impact Awards, an annual celebration recognizing and rewarding outstanding mission-driven individuals and organizations from around the world for their positive contributions to society. The seven winners — selected from nearly 3,000 applicants from more than 120 countries — were announced live at the awards ceremony, which
- 김갑성 기자
- 2025-10-08 21:00
Alpha Fusion and Kobe City Medical Center General Hospital Establish At-211 Investigational Drug Supply System

〜Driving Technology Transfer and Test Manufacturing Following Regulatory Approval to Launch Company-Led af-001 Trial〜 TOKYO, Oct. 8, 2025 -- Alpha Fusion Inc. (Alpha Fusion) is proud to announce a joint initiative with the Kobe City Medical Center General Hospital (KCGH) to establish a domestic supply system for investigational drugs utilizing Astatine-211 (At-211). This collaboration significantly advances the foundational work for what is expected to be the world's first company-sponsored clinical trial using At-211 (as of September 2025). KCGH has secured usage approv
- 김갑성 기자
- 2025-10-08 21:00
POMDOCTOR LIMITED Announces Pricing of Initial Public Offering

GUANGZHOU, China, Oct. 8, 2025 -- POMDOCTOR LIMITED (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the pricing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs have been approved for listing on the Nasdaq Global Market and are expected to commence trading on October 8, 2025 under the t
- 김갑성 기자
- 2025-10-08 20:00
AXA BetterMe Weekend Celebrates Fifth Anniversary

[ 메디채널 김갑성 기자 ] Championing holistic well-being and sustainable livingBuilding for a healthier future HONG KONG, Oct. 8, 2025 -- AXA Hong Kong and Macau (AXA) is excited to announce the return of its annual community event, the AXA BetterMe Weekend. Now in its fifth year, the carnival underscores AXA's commitment to promoting holistic well-being and advancing sustainable development within the community. This milestone edition will be held on 25 to 26 October (Saturday and Sunday) at AXA WONDERLAND, WestK, and feature AXA brand ambassador and award-winning actress and singer Sammi Ch
- 김갑성 기자
- 2025-10-08 17:10
BTL Files Patent Infringement Lawsuit Against WonderFace Device

PRAGUE, Oct. 8, 2025 -- BTL Group, a global leader in medical solutions, today announced that it has initiated an international patent infringement action before the Unified Patent Court against Lexter Microelectronic Engineering Systems S.L., the manufacturer of the WonderFace device. The lawsuit is based on BTL's patents related to its EMFACE® technology1. EMFACE® revolutionized facial lifting procedures by combining selective muscle stimulation with radiofrequency heating in distinct hands-free applicators, establishing an entirely new category of facial procedures.&
- 김갑성 기자
- 2025-10-08 16:14
Siemens Healthineers and National University Hospital Partner on Research to Advance Non-Invasive Liver Disease Diagnostics

Partnership will evaluate advanced ultrasound technologies to improve early detection and monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease Advancing ultrasound technologies that are safer, more accessible alternatives to invasive diagnostic procedures Research led by globally respected hepatologist Associate Professor Dan Yock Young SINGAPORE, Oct. 8, 2025 -- Siemens Healthineers and the National University Hospital (NUH) Singapore have announced a strategic research collaboration to advance diagnostic solutions for Metabolic Dysfunction-Associat
- 김갑성 기자
- 2025-10-08 11:15
Hope Medicine Inc. Announces Successful Completion of a Global Phase 2 Study of a Potential First-in-Class Endometriosis Treatment

[ 메디채널 김갑성 기자 ] HMI-115 demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 52% Most of the patients had normal menstrual periods No typical peri-menopausal symptoms were reported There were no significant changes in bone mineral density and sex hormone levels About 190 million women worldwide have endometriosis, making up a market size of $200billion SHANGHAI, Oct. 8, 2025 -- Hope Medicine Inc. ('HopeMed'), a clini
- 김갑성 기자
- 2025-10-08 09:08
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific

32 million people in Asia-Pacific live with heart failure, and this number is rising fast. New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. Urgent call for early diagnosis, digital and community-based care, and sustainable financing to save lives and reduce costs. SINGAPORE, Oct. 8, 2025 -- The Asia Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), in collaboration with Deloitte, has released a groundbreaking White Paper, Improving Heart Failure Policy and Management in Asia Pacific: Opportunities for Impact
- 김갑성 기자
- 2025-10-08 09:00
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled "GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial
- 김갑성 기자
- 2025-10-08 08:15
New Global Beauty & Wellbeing Report unveils Emotional Wellbeing as the True Face of Beauty

[ 메디채널 김갑성 기자 ] New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing STOCKHOLM, Oct. 8, 2025 -- Global beauty and wellbeing company, Oriflame, today releases its first Beauty & Wellbeing Report, revealing a major shift in how women around the world experience and define beauty. Based on a study of 3,500 women across seven countries, the report highlights the powerful role beauty plays in enhancing emotional wellbeing, self-confidence, and daily self-care. The findings reveal that beauty today is not about chasing perfection, but about f
- 김갑성 기자
- 2025-10-08 07:01

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 22시 40분